13F Holdings
中文EN

VICP Vicapsys Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1468639 · Fiscal year ends 12/31

Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-24.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-904.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3,053.8%
Debt / equity—
Current ratio0.03x
Interest coverage-62.88x

Cash quality & payout

Operating cash flow / net income0.09x
Accruals ratio-819.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31FY20192019-12-31
Income statement
Revenue—————
R&D expense$15,267$13,097$17,698$102,180$98,983
SG&A expense$96,431$60,198$35,790$46,957$54,111
Operating income-$1.05M-$984,790-$336,871-$765,844—
Interest expense$19,969————
Pretax income-$1.18M-$984,790-$236,871-$765,844-$1.03M
Net income-$1.18M-$984,790-$236,871-$765,844-$1.41M
EPS (basic)-0.03-0.03-0.01-0.04-0.13
EPS (diluted)-0.03-0.03-0.01-0.04-0.13
Weighted avg. shares (diluted)34.55M30.58M17.66M17.48M11.40M
Balance sheet
Cash & equivalents$9,422$14,097$217,295$1,269$264,166
Current assets$39,656$72,021$222,793$1,269$264,166
Intangibles——$371,520$402,849$434,273
Total assets$39,656$72,021$594,313$404,118$698,439
Current liabilities$1.97M$1.02M$715,964$853,224$396,482
Short-term debt$18,712————
Total liabilities$1.97M$1.02M$715,964$853,224$396,482
Shareholders' equity-$1.93M-$950,791-$121,651-$449,106$301,957
Shares outstanding32.07M31.19M19.75M17.48M17.48M
Cash flow statement
Operating cash flow-$417,524-$238,197-$443,974-$262,897-$970,264
Investing cash flow——$100,000——
Financing cash flow$412,849$34,999$560,000—$1.15M
Depreciation & amortization————$30,364
Stock-based compensation$20,697$105,650$4,326$14,781$118,649

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.